Denali Therapeutics (DNLI) said Wednesday it has submitted a biologics license application to the Center for Drug Evaluation and Research of the US Food and Drug Administration for accelerated approval of its Hunter syndrome investigational therapeutic, tividenofusp alfa.
Denali said it expects to complete the rolling submission in the first half of May, with a potential commercial launch in the US in late 2025 or early 2026.
Shares were up 6.6% in recent trading.
Price: 13.10, Change: +0.81, Percent Change: +6.59
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.